 Connection
Meredith Clement to Female
This is a "connection" page, showing publications Meredith Clement has written about Female.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.401 |
|
|
|
-
Irie WC, Corneli A, Perry B, Kelsey C, Bickham J, Davenport T, Naresh A, Holman S, Clement M. Start the Conversation: Development of a Training Program to Build OB/GYN Resident Capacity for PrEP Prescribing in Routine Care. J Int Assoc Provid AIDS Care. 2026 Jan-Dec; 25:23259582261488339.
Score: 0.034
-
Clement ME, Thomas J, Kelsey C, Jagneaux T, O'Neal C, Lim S, Widman S, Marcus J, Okeke NL, Wilson S. HEalth Record Optimization for Identifying Candidates for HIV PRe-Exposure Prophylaxis: A Community-Informed Approach to Model Development. AIDS Patient Care STDS. 2025 07; 39(7):266-272.
Score: 0.031
-
Clement ME, Perry B, McKenna K, Beckford J, Davenport T, Murray E, Magee V, Bickham JN, Siren J, Smith A, Lillis R, Corneli A. Identifying Implementation Strategies to Enhance HIV Pre-Exposure Prophylaxis Uptake Among Black Cisgender Women in New Orleans, Louisiana. AIDS Patient Care STDS. 2024 03; 38(3):144-150.
Score: 0.028
-
Lovett A, Luder R, Lillis RA, Butler I, Siren J, Gomez S, Kamis K, Obafemi O, Rowan SE, Baral S, Clement ME. Client Perspectives on the Development of a Rapid PrEP Initiative at a Sexual Health Center in New Orleans, Louisiana. J Int Assoc Provid AIDS Care. 2024 Jan-Dec; 23:23259582241258559.
Score: 0.028
-
Burns CM, Pung L, Witt D, Gao M, Sendak M, Balu S, Krakower D, Marcus JL, Okeke NL, Clement ME. Development of a Human Immunodeficiency Virus Risk Prediction Model Using Electronic Health Record Data From an Academic Health System in the Southern United States. Clin Infect Dis. 2023 01 13; 76(2):299-306.
Score: 0.026
-
Corneli A, Perry B, Taylor J, Beckford J, Molokwu N, Reif S, Wilson J, Gulden C, Bickham J, Siren J, Thompson W, Clement ME. HIV Prevention During the COVID-19 Pandemic: Sexual Activity and PrEP Use Among Black Same-Gender-Loving Men and Black Cisgender Women. AIDS Educ Prev. 2022 04; 34(2):142-157.
Score: 0.025
-
Clement ME, Kofron R, Landovitz RJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020 01; 15(1):19-26.
Score: 0.021
-
Clement ME, Okeke NL, Munn T, Hunter M, Alexis K, Corneli A, Seña AC, McGee K, McKellar MS. Partnerships Between a University-Affiliated Clinic and Community-Based Organizations to Reach Black Men Who Have Sex With Men for PrEP Care. J Acquir Immune Defic Syndr. 2018 02 01; 77(2):e25-e27.
Score: 0.019
-
Clement ME, Lin L, Navar AM, Okeke NL, Naggie S, Douglas PS. Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome. Medicine (Baltimore). 2018 Feb; 97(6):e9849.
Score: 0.019
-
Clement ME, Seidelman J, Wu J, Alexis K, McGee K, Okeke NL, Samsa G, McKellar M. An educational initiative in response to identified PrEP prescribing needs among PCPs in the Southern U.S. AIDS Care. 2018 05; 30(5):650-655.
Score: 0.018
-
Clement ME, Hicks CB. Syphilis on the Rise: What Went Wrong? JAMA. 2016 Jun 07; 315(21):2281-3.
Score: 0.017
-
Clement ME, Park LP, Navar AM, Okeke NL, Pencina MJ, Douglas PS, Naggie S. Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. Clin Infect Dis. 2016 08 01; 63(3):407-13.
Score: 0.016
-
Clement ME, Okeke NL, Hicks CB. Treatment of late-stage syphilis--reply. JAMA. 2015 Mar 03; 313(9):969-70.
Score: 0.015
-
Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014 Nov 12; 312(18):1905-17.
Score: 0.015
-
Moeser MJ, Council OD, Long N, Kincer L, Dennis AM, Eron J, Wohl D, Farel CE, Dittmer DP, Pluta L, Nelson J, Mohammadi A, Etemad B, Li JZ, McGann H, Smit E, Clement M, Yau T, Menezes P, Bowman NM, Zhou S, Joseph SB. A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage. J Infect Dis. 2026 Jun 16; 233(6):1005-1014.
Score: 0.008
-
Llibre JM, Iniesta C, Tittle V, Clement M, Rivero Á, Armenteros-Yeguas I, Álvarez-López P, Ryan P, Arribas JR, Moreno S. Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations. J Antimicrob Chemother. 2026 Feb 02; 81(3).
Score: 0.008
-
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 03; 392(13):1261-1276.
Score: 0.007
-
Gottlieb RL, Clement M, Cook P, Deveikis A, Foong KS, Robinson P, Slim J, Spak CW, Buelens A, Callewaert K, De Meyer S, Mo WL, Verbrugge I, Van Wesenbeeck L, Zhuang Y, Chien JW, Opsomer M, Van Landuyt E. The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19. J Infect. 2024 Oct; 89(4):106241.
Score: 0.007
-
Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV. 2023 12; 10(12):e767-e778.
Score: 0.007
-
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Ann Intern Med. 2022 04; 175(4):479-489.
Score: 0.006
-
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 08 12; 385(7):595-608.
Score: 0.006
-
Cohen MS, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, Stemer A, Mayer SM, Wohl D, Brengle B, Montague BT, Frank I, McCulloh RJ, Fichtenbaum CJ, Lipson B, Gabra N, Ramirez JA, Thai C, Chege W, Gomez Lorenzo MM, Sista N, Farrior J, Clement ME, Brown ER, Custer KL, Van Naarden J, Adams AC, Schade AE, Dabora MC, Knorr J, Price KL, Sabo J, Tuttle JL, Klekotka P, Shen L, Skovronsky DM. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA. 2021 07 06; 326(1):46-55.
Score: 0.006
-
Alenezi F, Bloomfield GS, Okeke NL, Velagapudi P, Abudaqa L, Ijioma N, Dunning A, Alajmi H, Clement ME, Shah SH, Naggie S, Velazquez EJ. Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. Am J Cardiol. 2019 09 15; 124(6):966-971.
Score: 0.005
-
Bedoya AD, Clement ME, Phelan M, Steorts RC, O'Brien C, Goldstein BA. Minimal Impact of Implemented Early Warning Score and Best Practice Alert for Patient Deterioration. Crit Care Med. 2019 01; 47(1):49-55.
Score: 0.005
-
Naggie S, Clement M, Lusk S, Osinusi A, Himmel T, Lucas JE, Thompson WJ, Dubois L, Moseley MA, Clark PJ, Kottilil S, Patel K. Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. Proteomics Clin Appl. 2019 05; 13(3):e1800006.
Score: 0.005
-
Okeke NL, Alenezi F, Bloomfield GS, Dunning A, Clement ME, Shah SH, Naggie S, Velazquez EJ. Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. J Card Fail. 2018 Aug; 24(8):496-503.
Score: 0.005
-
Okeke NL, Craig DM, Muehlbauer MJ, Ilkayeva O, Clement ME, Naggie S, Shah SH. Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study. Metabolomics. 2018 03; 14(3).
Score: 0.005
-
Clifton DC, Clement ME, Holland TL, Cox GM, Dicks KV, Stout JE. Suboptimal HIV Testing Among Patients Admitted With Pneumonia: A Missed Opportunity. AIDS Educ Prev. 2017 08; 29(4):377-388.
Score: 0.004
-
Okeke NL, Chin T, Clement M, Chow SC, Hicks CB. Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. AIDS Care. 2016; 28(4):475-82.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|